Piper Sandler analyst David Westenberg lowered the firm’s price target on Exact Sciences (EXAS) to $75 from $85 following quarterly ...

Wells Fargo analyst Brandon Couillard lowered the firm’s price target on Exact Sciences (EXAS) to $70 from $75 and keeps an Overweight rating on the shares. The firm notes Exact Sciences reported a ...

Exact Sciences Corporation EXAS reported a net loss of 21 cents in third-quarter 2024 compared with break-even earnings in ...

EXACT Sciences Corp. is a cancer screening and diagnostics company. The firm focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called ...

MADISON, Wis. (AP) — MADISON, Wis. (AP) — Exact Sciences Corp. (EXAS) on Tuesday reported a loss of $38.2 million in its third quarter. On a per-share basis, the Madison, Wisconsin-based ...

November 05, 2024--(BUSINESS WIRE)--Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the Company generated revenue of $709 ...

Exact Sciences (NASDAQ:EXAS) has filed a lawsuit in federal court alleging that Geneoscopy’s ColoSense product infringes upon a key patent for its colorectal cancer screening test Cologuard.

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

Stocks for Exact Sciences leaped 33% after it announced the acquisition of liquid biopsy rival Thrive and UK start-up Base Genomics. Exact Sciences said it has agreed to buy Thrive for a cash and ...

FDA Clears Exact Sciences' Next-Generation Colorectal Cancer Diagnostic Test Exact Sciences' Cologuard Plus test, now FDA-approved, offers a non-invasive screening option for adults 45+ at average ...

Exact Sciences reports quarterly GAAP losses of 21 cents per share, which missed the analyst consensus estimate for losses of 20 cents. Quarterly sales of $709 million miss the consensus estimate ...